Vietnam National Cancer Hospital (K Hospital), Hanoi
September 2021 – Present
Awards & Achievements
International Clinical Research Scholars (ICRS) Program Award
2026–2027
ASCO Asia Pacific Regional Council
TLCS Research Investigator Award
November 2023
ASPIRE Workshop, Taipei
Publications
Cam Phuong Pham, Hung Kien Do, Anh Tu Do, Tuan Khoi Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Van Luan Pham, Minh Hai Nguyen, Thi Thai Hoa Nguyen, Thi Bich Phuong Nguyen, Ha Thanh Vu, Thi Thuy Hang Nguyen, Van Thai Pham, Le Huy Trinh, Khac Dung Nguyen, Hoang Gia Nguyen, Cong Minh Truong, Tran Minh Chau Pham, Van Tai Nguyen. Optimizing afatinib dosage: enhancing treatment outcomes and minimizing toxicities in advanced EGFR-mutated non-small cell lung cancer patients in Vietnam. Ther Adv Med Oncol. 2025.doi: 10.1177/17588359251382665
Van Luan Pham, Cam Phuong Pham, Thi Thai Hoa Nguyen, Tuan Khoi Nguyen, Minh Hai Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Hung Kien Do, Ha Thanh Vu, Thi Thuy Hang Nguyen, Van Thai Pham, Le Huy Trinh, Hoang Gia Nguyen, Cong Minh Truong, Tran Minh Chau Pham, Thi Bich Phuong Nguyen. Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring epidermal growth factor receptor-G719X mutation treated by afatinib: real-world data from a multicenter study in Vietnam. Ther Adv Respir Dis. 2025.doi: 10.1177/17534666251341747
Thanh Ha Vu, Thi Hoa Thai Nguyen, To Van Ta, Minh Cong Truong, Thang Bui Xuan, Anh Tuan Nguyen, Cao Van Nguyen, Hang Thuy Thi Nguyen, Tuyet Thi Doan, Thanh Thi Vu, Dung Khac Dinh, Giang Vinh Le, Hung Huy Hoang, Chi Khanh Duong, Linh Khanh Dao. Real-World Evidence for First-Line afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X/L861Q/S768I. Cancer Control. 2025.doi: 10.1177/10732748251386133
Hoa Nguyen, Quang Le, Huyen Phung, Quang Nguyen, Huong Vu, Minh Truong. Real-World Effectiveness and Safety of Ribociclib Plus Aromatase Inhibitors in Patients with HR+/HER2- Metastatic Breast Cancer: A Multicenter Experience from Vietnam. Asian Pac J Cancer Prev. 2025.doi: 10.31557/apjcp.2025.26.11.4209
Van Luan Pham, Tuan Anh Le, Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Minh Hai Nguyen, Thi Anh Thu Hoang, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi Thuy Hang Nguyen, Van Thai Pham, Le Huy Trinh, Khac Dung Nguyen, Hoang Gia Nguyen, Cong Minh Truong, Tran Minh Chau Pham, Thi Bich Phuong Nguyen. Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam. Ther Adv Med Oncol. 2024.doi: 10.1177/17588359241242972
Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Thi Anh Thu Hoang, Tuan Anh Le, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Van Luan Pham, Minh Hai Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi Thuy Hang Nguyen, Van Thai Pham, Le Huy Trinh, Khac Dung Nguyen, Hoang Gia Nguyen, Cong Minh Truong, Tran Minh Chau Pham, Thi Bich Phuong Nguyen. A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam. BMC Cancer. 2024.doi: 10.1186/s12885-024-11891-w
Thanh Vu, Hoa Nguyen, Linh Dao, Chi Duong, Cao Nguyen, Tuyet Doan, Hang Nguyen, Hung Hoang, Dung Dinh, Giang Le, Thanh Vu, Minh Truong, Long Nguyen. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. Asian Pac J Cancer Prev. 2021.doi: 10.31557/apjcp.2021.22.5.1581
Huyen Phung, Minh Truong, Long Nguyen, Anh Dang, Thanh Vu, Hoa Nguyen. Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam. Asian Pac J Cancer Prev. 2021.doi: 10.31557/apjcp.2021.22.3.853Corresponding author